Source: BioSpace Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on identifying, in-licensing and developing high-potential marketed and development-stage drugs and drug candidates, today announced it ranked number 10 in Deloitte’s 2019 Technology Fast 500™, an annual ranking of the fastest-growing North American companies in the technology,…...
Stryker to buy orthopedic device maker Wright Medical for $4B
Source: FierceBiotech Stryker is moving to acquire fellow devicemaker Wright Medical in a $4 billion play to gain a stronger foothold in fast-growing orthopedic segments. The Amsterdam and Memphis, Tennessee-based Wright Medical posted $836 million in global net sales for 2018, driven largely by its products for the upper and…...
UCB strikes $2.5B deal to buy Ra for rival to Alexion’s Soliris
Source: FierceBiotech UCB Pharma has struck a $2.5 billion (€2.2 billion) deal to acquire Ra Pharmaceuticals. The takeover will give UCB control of a phase 3 rival to Alexion’s Soliris that some analysts have tipped to rack up blockbuster sales. Ra is focused on a once-daily, self-administered, subcutaneous C5 inhibitor called zilucoplan.…...
Cassiopea Anounces FDA Submission of New Drug Application for Clascoterone Cream 1%, The First New Mechanism of Action for Acne in Nearly 40 Years
Source: Cassiopea Cassiopea SpA (SIX: SKIN), a specialty pharmaceutical company developing and commercializing prescription drugs with novel mechanisms of action (MOA) to address long-standing and essential dermatological conditions, announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking marketing approval…...
AbbVie Looks Beyond Humira with $63 Billion Deal for Botox-Maker Allergan
Source: Reuters Drugmaker AbbVie Inc said on Tuesday it would buy Botox-maker Allergan Plc for about $63 billion, grabbing control of the biggest name in medical aesthetics to help reduce its reliance on blockbuster arthritis treatment Humira. AbbVie has been under pressure to diversify its portfolio as Humira, the world’s…...
Pharma Celgene, Say Goodbye to Otezla: BMS Agrees to Sell Psoriasis Drug to Clear $74B Merger
Source: FiercePharma With the Federal Trade Commission (FTC) sweating the details of Bristol-Myers Squibb and Celgene’s proposed $74 billion merger, all eyes were on the companies’ combined psoriasis portfolio, which regulators feared would corner the market. The feds found a solution: You can have your merger, but you don’t get…...
Bellus Medical, the Aesthetics Division of Crown Laboratories, Announces Acquisition of Healeon Medical’s HD PRP System for Aesthetic Marketplace
Source: PRNewswire DALLAS, May 23, 2019 /PRNewswire/ -- Bellus Medical is proud to announce the acquisition of Healeon Medical, Inc.'s HD PRP system for the aesthetic marketplace. This specialized system is designed to meet the demands of busy practices seeking higher volume and higher yield Platelet Rich Plasma procedures; with the most efficient and…...
Encore Dermatology Inc. Acquires SERNIVO®, TRIANEX® and PROMISEB®
Source: BusinessWire MALVERN, Pa.--(BUSINESS WIRE)--Encore Dermatology Inc. announced today that it has acquired rights for SERNIVO® (betamethasone dipropionate) Spray, 0.05%, as well as rights to market and distribute TRIANEX® 0.05% (Triamcinolone Acetonide Ointment, USP) and PROMISEB® Topical Cream in the United States from Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE:…...
Allergan Acquires Envy Medical, Inc., Adding Skin Resurfacing Dermalinfusion System to Best-in-Class Medical Aesthetics Portfolio
Source: PRNewswire DUBLIN, March 26, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced it has completed the acquisition of Envy Medical, Inc., a privately held company with proprietary technology in skin resurfacing. The acquisition enhances Allergan's best-in-class Medical Aesthetics portfolio with the addition of Envy's Dermalinfusion, a…...
Biofrontera, Inc., USA, acquires Cutanea Life Sciences, Inc., USA
Source: GlobeNewswire Leverkusen, Germany, March 25, 2019 (GLOBE NEWSWIRE) -- Biofrontera Inc., USA (“Biofrontera”), a wholly owned subsidiary of Biofrontera AG (NASDAQ ticker symbol: BFRA, ISIN: DE0006046113), today entered into an agreement to acquire all shares in Cutanea Life Sciences, Inc., USA (“Cutanea”) through its subsidiary Biofrontera Newderm LLC as…...